Development of gastrointestinal track-targeted biologics to improve the treatment of inflammatory bowel disease (IBD)

开发胃肠道靶向生物制剂以改善炎症性肠病（IBD）的治疗

• 批准号: 450939
• 负责人: Gariepy Jean
• 金额: $ 63.25万
• 依托单位: Sunnybrook Research Institute (Toronto, Ontario)
• 依托单位国家: 加拿大
• 项目类别: Operating Grants
• 财政年份: 2021
• 资助国家: 加拿大
• 起止时间: 2021-09-01 至 2026-09-01
• 项目状态: 未结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=450939&lang=en
• 关键词: Anti-Inflammatory Agents; Anti-Tnf Alpha Agents; Bi-Specific Proteins; Carcinoembryonic Antigen; Crohn'S Disease; Intestinal Bowel Disease; Localized Delivery To The Gut; Single Chain Fv; Targeted Biologics; Ulcerative Colitis

Inflammatory bowel disease (IBD) is a term that groups together chronic inflammatory diseases of the digestive tract, notably Crohn's disease and ulcerative colitis. It is projected that IBD will affect about 1% of our country's population by 2030. IBD ty

炎症性肠病（IBD）是消化道慢性炎症性疾病的统称，主要是克罗恩病和溃疡性结肠炎。据预测，到2030年，IBD将影响我国约1%的人口。IBD泰